Are you a Health Professional? Jump over to the doctors only platform. Click Here

Testing of new obesity drug to help reduce heart disease

Print Friendly, PDF & Email

Tularik has initiated Phase I clinical testing of T71, an oral drug candidate for the treatment of obesity. T71 is expected to help obese patients lose weight by reducing appetite and increasing metabolic rate. In preclinical studies, T71 was also shown to decrease insulin and lipid levels, which are predictors of the obesity-related co-morbidities, diabetes and heart disease, respectively.

Tularik has initiated Phase I clinical testing of T71, an oral drug candidate for the treatment of obesity. T71 is expected to help obese patients lose weight by reducing appetite and increasing metabolic rate. In preclinical studies, T71 was also shown to decrease insulin and lipid levels, which are predictors of the obesity-related co-morbidities, diabetes and heart disease, respectively. This Phase I trial is being conducted in overweight to obese healthy adult volunteers in the United Kingdom. The study will evaluate the safety and pharmacokinetics of single doses of T71. In addition, the effect of T71 on appetite, satiety and other markers of activity will be measured. The single ascending dose study will be followed by a multiple ascending dose study, also in overweight to obese healthy volunteers. “Obesity and its associated co-morbidities, including diabetes and coronary heart disease, are creating serious individual and public health consequences worldwide,” said Michael Levy, M.D., Vice President of Development and Chief Medical Officer of Tularik. “We are hopeful that T71, with its dual mode of action, will result in clinically meaningful weight loss for patients suffering from obesity.” (Source: Cardiac Life Centre: February 2004)


Print Friendly, PDF & Email

Dates

Posted On: 17 February, 2004
Modified On: 3 December, 2013

Tags



Created by: myVMC